# US 2025/0144041 A1 · Pharmaceutical composition for treating retinitis pigmentosa

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144041 A1
- Document ID: US20250144041A1
- Status: Published application
- Kind: A1
- Application number: 18/832,713
- Filed: 2023-01-26
- Published: 2025-05-08
- Earliest claimed: 2022-01-28
- Assignees: Kyushu University, National University Corporation; SENTAN Pharma Inc.
- Applicants: Kyushu University, National University Corporation; SENTAN Pharma Inc.
- Inventors: Yusuke MURAKAMI; Koh-Hei SONODA; Yasuhiro IKEDA; Tsuneyuki KOGA; Takeru MATSUO; Yojiro EGUCHI; Hironobu FURUIE
- Web page: https://patentgrep.com/patent/US20250144041A1

## CPC

- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 31/47: Quinolines; Isoquinolines
- A61P 27/02: Ophthalmic agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

A pharmaceutical composition for treating retinitis pigmentosa that includes statin-loaded nanoparticles. The pharmaceutical composition is used in a method of treating retinitis pigmentosa involving administering to a subject in need thereof the pharmaceutical composition that includes statin-loaded nanoparticles.

## Claims

### Claim 1

A method for treating retinitis pigmentosa comprising administering a pharmaceutical composition comprising statin-loaded nanoparticles to a subject in need thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the statin is pitavastatin or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the statin is pitavastatin calcium.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the statin-loaded nanoparticles contain 1 to 15% by weight of statin.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the statin-loaded nanoparticles comprise PLGA.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the statin-loaded nanoparticles have a particle size of 50 to 300 nm.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition comprises 1 to 15% by weight of the statin-loaded nanoparticles, based on a total weight of pharmaceutical composition.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is administered at a dose of 0.01 mg/kg to 0.5 mg/kg per day of statin.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is administered intravenously.
